DexCom Inc. Common Stock (NASDAQ: DXCM)
The Complaint alleges that during the Class Period, Defendants failed to disclose the true state of DexCom’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential, and that as a result of their purchases of DexCom’s common stock during the Class Period, Plaintiff and other members of the Class suffered economic loss.